Toronto-Built CryoSPARC Software Enables Coronavirus Vaccine Breakthrough
A significant breakthrough in the global effort to develop a coronavirus vaccine has been linked to research origins in Toronto. On February 15, 2020, researchers from the University of Texas at Austin and the National Institutes of Health published the high-resolution 3D molecular structure of the SARS-CoV-2 spike protein in the journal Science. This achievement provides the first atomic-scale map of the virus component responsible for infecting human cells, marking a critical step toward creating effective vaccines and antiviral drugs. The mapping was made possible by CryoSPARC, a specialized software package utilizing advanced algorithms for computer vision and machine learning. These algorithms were developed by a team associated with the University of Toronto, including PhD student Ali Punjani, MSc student Haowei Zhang, former student Marcus Brubaker, and Vector Institute Faculty Member David Fleet. Punjani co-founded Structura Biotechnology to commercialize CryoSPARC, aiming to reduce uncertainty in drug discovery while offering the tool free to academics. This collaboration highlights the pivotal role of Canadian artificial intelligence and structural biology expertise in addressing urgent global health challenges.
Wire timeline
Toronto-Built CryoSPARC Software Enables Coronavirus Vaccine Breakthrough
A significant breakthrough in the global effort to develop a coronavirus vaccine has been linked to research origins in Toronto. On February 15, 2020, researchers from the University of Texas at Austin and the National Institutes of Health published the high-resolution 3D molecular structure of the SARS-CoV-2 spike protein in the journal Science. This achievement provides the first atomic-scale map of the virus component responsible for infecting human cells, marking a critical step toward creating effective vaccines and antiviral drugs. The mapping was made possible by CryoSPARC, a specialized software package utilizing advanced algorithms for computer vision and machine learning. These algorithms were developed by a team associated with the University of Toronto, including PhD student Ali Punjani, MSc student Haowei Zhang, former student Marcus Brubaker, and Vector Institute Faculty Member David Fleet. Punjani co-founded Structura Biotechnology to commercialize CryoSPARC, aiming to reduce uncertainty in drug discovery while offering the tool free to academics. This collaboration highlights the pivotal role of Canadian artificial intelligence and structural biology expertise in addressing urgent global health challenges.
Vector Institute for Artificial Intelligence